BioNotebook: Offerings slow on market woes, others raise venture cash

It was a difficult week for biotechnology fundraising, at least in the public markets, given the shaky ongoing dialog about the state of the biotech stock investing.

It was a difficult week for biotechnology fundraising, at least in the public markets, given the shaky ongoing dialog about the state of the biotech stock investing.

Generalist stock investors: The biotech sky is falling!

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category